Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Epithelial-mesenchymal transition (EMT) is a phenotypic conversion that facilitates organ morphogenesis and tissue remodeling in physiological processes, such as embryonic development and wound healing. A similar phenotypic conversion is also detected in fibrotic diseases and neoplasia, and is associated with disease progression. EMT in cancer epithelial cells often seems to be an incomplete and bidirectional process. In this Review, we discuss the phenomenon of EMT as it pertains to tumor development, focusing on exceptions to the commonly held rule that EMT promotes invasion and metastasis. We also highlight the role of RAS-controlled signaling mediators, ERK1, ERK2 and phosphatidylinositol 3-kinase, as microenvironmental responsive regulators of EMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs facilitate and modulate EMT through the production of regulatory molecules, namely TGF-b, E-cadherin and micro-RNA, resulting in more invasive phenotype [46], [47].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“70-gene prognostic signature CCL2, MT1X and MT2A van‘t Veer et al. (2002)46”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601018 · Cited by 2,019
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
An Overview of Epithelio-Mesenchymal Transformation
Hay, E. D. (1995) · Cells Tissues Organs · doi:10.1159/000147748 · Cited by 1,567
The Snail genes as inducers of cell movement and survival: implications in development and cancer
Barrallo-Gimeno, A., & Nieto, M. A. (2005) · Development · doi:10.1242/dev.01907 · Cited by 1,394
Cited by
Items 101–200 of 253
Wang, D., Han, S., Wang, X., Peng, R., & Li, X. (2015) · Medical Oncology · doi:10.1007/s12032-014-0461-2 · Cited by 51
“EMT is a key event in the tumor invasion and metastasis process which enables epithelial cells to acquire invasive mesenchymal phenotype [24, 25].”
BackgroundXu, J., Song, Z., Guo, Q., & Li, J. (2016) · BioMed Research International · doi:10.1155/2016/1490738 · Cited by 53
“transition (EMT), a process in which epithelial cells lose cell-cell adhesion and cell polarity and acquire properties of mesenchymal cells, which results in cancer progression, metastasis, and multidrug resistance in cancer [32–35].”
BackgroundFhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Joannes, A., Grelet, S., Duca, L., Gilles, C., Kileztky, C., Dalstein, V., Birembaut, P. L., Polette, M., & Nawrocki‐Raby, B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0386-t · Cited by 53
“Tumor cells also acquire degradative properties against extracellular matrix components through their ability to produce themselves high levels of proteases such as matrix metalloproteases (MMP) among which MMP-2, MMP-9, and MMP-14 (7, 8).”
BackgroundLuo, Q., Wu, X., Chang, W., Zhao, P., Nan, Y., Zhu, X., Katz, J. P., Su, D., & Liu, Z. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0475-6 · Cited by 51
Mimeault, M., & Batra, S. K. (2010) · PubMed · doi:10.14670/hh-25.1057 · Cited by 56
“…et al., 2006; Bailey et al., 2007; Hermann et al., 2007; Mimeault and Batra, 2007b; Moustakas and Heldin, 2007; Shah et al., 2007; Shipitsin et al., 2007; Spaderna et al., 2007; Wang et al., 2007b; Das et al., 2008; Mani et al., 2008; Morel et al., 2008; Storci et al., 2008; Turley et al., 2008).”
BackgroundInfluentialTargeting glycosphingolipids for cancer immunotherapy
Yu, J., Hung, J., Wang, S., Cheng, J., & Yu, A. L.-T. (2020) · FEBS Letters · doi:10.1002/1873-3468.13917 · Cited by 50
The FHL2 regulation in the transcriptional circuitry of human cancers
Cao, C. Y., Mok, S. W.-F., Cheng, V. W.-S., & Tsui, S. K. (2015) · Gene · doi:10.1016/j.gene.2015.07.043 · Cited by 50
“The structural integrity of membraneassociated E-cadherin-β-catenin complex is an important determinant for the induction of EMT and therefore indicates the role of FHL2 in cancer migration and invasion (Zhang et al., 2010).”
BackgroundMMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer
Vos, M. C., Hollemans, E., Ezendam, N. P. M., Feijen, H., Boll, D., Pijlman, B. M., van der Putten, H. W. H. M., Klinkhamer, P. J. J. M., Kuppevelt, T. H. V., van der Wurff, A. A. M., et al. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0262-7 · Cited by 45
“EMT-like changes result in down-regulation of epithelial markers such as E-cadherin and cytokeratins and increased expression of mesenchymal markers such as vimentin [1, 3, 4].”
BackgroundZhang, W., Wang, J., Zou, B., Sardet, C., Li, J., Lam, C. S. C., Ng, L., Pang, R., Hung, I. F., Tan, V. P. Y., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.045 · Cited by 43
Kim, S., Park, Y. R., Lee, S. T., & Kim, S. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4166 · Cited by 41
Yi, B.-R., Kim, T., Kim, Y.-S., & Choi, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2695 · Cited by 39
Yao, W., Peng, Y., Wu, M., Zhang, W., Zhang, M., Xie, R., Zhang, P., Bai, Y., Zhao, J., Li, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9457 · Cited by 40
Zeng, Q., Li, Z., Zhao, X., Guo, L., Yu, C., Qin, J., Zhang, S., Zhang, Y., & Yang, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6835 · Cited by 43
Growth factor- and cytokine-driven pathways governing liver stemness and differentiation
Sánchez, A., & Fabregat, I. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i41.5148 · Cited by 47
Cakouros, D., Raices, R. M., Gronthos, S., & Glackin, C. A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22651 · Cited by 41
“…cancers [Savagner et al., 1994; Hay, 1995; Thiery and Chopin, 1999; Thiery, 2002; Kalluri and Neilson, 2003; Thiery, 2003; Agiostratidou et al., 2007; Kokkinos et al., 2007; Moustakas and Heldin, 2007; Baum et al., 2008; Gavert and BenZe’ev, 2008; Turley et al., 2008; Yang and Weinberg, 2008].”
BackgroundEpithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models
Yumul, R., Richter, M., Lu, Z., Saydaminova, K., Wang, H., Wang, C.-H. K., Carter, D., & Lieber, A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.022 · Cited by 42
“28,29 In the case of DSG2-interacting Ads, specifically Ad3, Ad14, and Ad14P1, 12 pentons self-assemble into dodeca-mers (penton-dodecahedral particles [PtDd]) with a diameter of * 30 nm that are released from infected cells early during infection before cell lysis.”
Veiseh, M., & Turley, E. A. (2011) · Integrative Biology · doi:10.1039/c0ib00096e · Cited by 38
Self-citationLam, C. S.-C., Ng, L., Chow, A. K.-M., Wan, T. M.-H., Yau, S., Cheng, N. S.-M., Wong, S. K., Man, J. H.-W., Lo, O. S., Foo, C. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15844 · Cited by 42
“Epithelialmesenchymal transition (EMT), which is characterized by the cell reprogramming and transition from epithelial phenotype to mesenchymal phenotype, is a pivotal process that affects the tumor cell metastasis by altering cell-cell contact and cell-extracellular matrix (ECM) interactions [7, 8].”
BackgroundWu, Y., Zhang, Y., Wang, D., Zhang, Y., Zhang, J., Zhang, Y., Xu, L., Wang, T., Wang, S., Zhang, Q., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03008-5 · Cited by 44
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
Qiu, C., Liu, Y., Mei, Y., Zou, M., Zhao, Z., Ye, M., & Wu, X. (2018) · Aging · doi:10.18632/aging.101587 · Cited by 41
“The EMT is a complex process in which epithelial cells develop a mesenchymal phenotype; it plays a vital role in the early stage of tumor cell metastasis as cells lose intercellular cohesion and use an increased migratory and invasion ability to spread into distant tissues [32].”
BackgroundYan, S., Chu, D., Qiu, H., Xie, Y., Wang, C., Zhang, J., Li, W., & Guo, R. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14161 · Cited by 37
RetractedEvaluation of molecular markers of mesenchymal phenotype in melanoma
Mikesh, L. M., Kumar, M., Erdag, G., Hogan, K. T., Molhoek, K. R., Mayo, M. W., & Slingluff, C. L. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833fafb4 · Cited by 37
Xi, Y., Wei, Y., Sennino, B., Ulsamer, A., Kwan, I., Brumwell, A. N., Tan, K., Aghi, M. K., McDonald, D. M., Jablons, D. M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.530 · Cited by 32
Zanjani, L. S., Madjd, Z., Abolhasani, M., Rasti, A., Fodstad, Ø., Andersson, Y., & Asgari, M. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0142 · Cited by 36
Can oncology recapitulate paleontology? Lessons from species extinctions
Walther, V., Hiley, C. T., Shibata, D. K., Swanton, C., Turner, P. E., & Maley, C. C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.12 · Cited by 41
Premetastatic niche: ready for new therapeutic interventions?
Zoccoli, A., Iuliani, M., Pantano, F., Imperatori, M., Intagliata, S., Vincenzi, B., Marchetti, P., Papapietro, N., Denaro, V., Tonini, G., et al. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.656092 · Cited by 38
“Although the EMT program is necessary for normal development, the aberrant activation of EMT contributes to various pathologic conditions, including fibrosis and carcinoma progression [25,26].”
BackgroundOgunwobi, O. O., & Liu, C. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.007 · Cited by 36
Psyrri, A. K., Lee, J., Pectasides, E., Vassilakopoulou, M., Kosmidis, E. K., Burtness, B. A., Rimm, D. L., Wanebo, H. J., & Forastiere, A. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0113 · Cited by 34
“ERK1/2 can also enhance the metastatic potential of tumor cells by inducing Slug, Snail, and epithelial-to-mesenchymal transition (EMT; ref.”
BackgroundInfluentialKong, X., Liu, F., & Gao, J. X. (2016) · Oncotarget · doi:10.18632/oncotarget.11800 · Cited by 35
Hyperbaric oxygen therapy can ameliorate the EMT phenomenon in keloid tissue
Zhang, M., Liu, S., Guan, E., Liu, H., Dong, X., Yan, H., Zhang, X., Zhao, P., Liu, X., Pan, S., et al. (2018) · Medicine · doi:10.1097/md.0000000000011529 · Cited by 35
“Typical cell markers (epithelial and mesenchymal markers) play a significant role in identifying this process, which is marked by the higher expression of mesenchymal markers (vimentin and fibronectin) and lower expression of epithelial markers (E-cadherin and ZO-1).([27,28]) EMT is required for several early processe…”
BackgroundShen, A., Chen, H., Chen, Y., Lin, J., Lin, W., Liu, L., Sferra, T. J., & Peng, J. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/679436 · Cited by 38
ESRP1 Induces Cervical Cancer Cell G1-Phase Arrest Via Regulating Cyclin A2 mRNA Stability
Chen, Z., Jing, Y., Yu, J., Jin, Z.-S., Li, Z., He, T., & Su, X.-Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153705 · Cited by 32
Palena, C., Fernando, R. I., Litzinger, M. T., Hamilton, D. H., Huang, B., & Schlom, J. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010367 · Cited by 32
Neoplastic stem cells: Current concepts and clinical perspectives
Schulenburg, A., Brämswig, K. H., Herrmann, H., Karlic, H., Mirkina, I. I., Hubmann, R., Laffer, S., Marian, B., Shehata, M. M., Krepler, C., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.001 · Cited by 35
“[179] Turley EA, Veiseh M, Radisky DC, Bissell MJ.”
BackgroundToward a stem cell gene therapy for breast cancer
Li, Z., Liu, Y., Tuve, S., Ye, X., Fan, X., Min, L., Feng, Q., Kiviat, N., Kiem, H., Disis, M. L., et al. (2009) · Blood · doi:10.1182/blood-2008-10-187237 · Cited by 35
He, F., Melamed, J., Tang, M., Huang, C., & Wu, X. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3067 · Cited by 32
“Finally, as with other epithelial cells, RAS activation and p53 deficiency are both strong promoters of EMT (54, 55).”
Cheng, Z.-X., Guo, Y., Yang, Y., Kan, J., Dai, S., Helian, M., Li, B., Xu, J., & Liu, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4846 · Cited by 31
“Cancer cells can gain the capacity to invade adjacent tissues, break through the basement membrane, and finally enter the bloodstream when acquiring the mesenchymal phenotype through EMT (38).”
BackgroundThe mechanism of epithelial-mesenchymal transition induced by TGF-β1 in neuroblastoma cells
Shao, J., Gao, Z., Huang, W., & Lu, Z.-B. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3954 · Cited by 30
“Although, TGF-β 1 is known to induce EMT (10), the mechanism of this induction in neuroblastoma is poorly understood.”
Sriramulu, S., Sun, X., Malayaperumal, S., Ganesan, H., Zhang, H., Ramachandran, M., Banerjee, A., & Pathak, S. (2021) · Cells · doi:10.3390/cells10061497 · Cited by 30
Wang, W. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000696 · Cited by 35
“EMT is a distinct feature occurring during embryonic development and tumor progression towards metastasis (25,26).”
BackgroundPark, J., & Yoon, J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.02.014 · Cited by 29
Wang, X., Ji, S., Ma, Y., Xing, X., Zhou, Y., Xu, X., Song, J., Wang, S., Jiang, W., Wang, X., et al. (2020) · Cytotechnology · doi:10.1007/s10616-020-00402-x · Cited by 29
Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Krasnapolski, M. A., Todaro, L. B., & Joffé, E. B. D. K. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798377021 · Cited by 29
Argast, G. M., Mercado, P., Mulford, I. J., O’Connor, M., Keane, D. M., Shaaban, S. A., Epstein, D. M., Pachter, J. A., & Kan, J. L. C. (2010) · Cells Tissues Organs · doi:10.1159/000320179 · Cited by 28
“, 2003] with an overlap of 13 genes between the 2 lists [Turley et al., 2008].”
BackgroundInfluentialZou, H., Mou, X., & Zhu, B. (2022) · Global Challenges · doi:10.1002/gch2.202200094 · Cited by 34
MicroRNAs and Bone Metastasis: A New Challenge
Croset, M., Santini, D., Iuliani, M., Fioramonti, M., Zoccoli, A., Vincenzi, B., Tonini, G., & Pantano, F. (2014) · Molecules · doi:10.3390/molecules190710115 · Cited by 27
“During EMT, transformation of normal epithelial cells disrupts cell-cell and cell extracellular matrix contacts and migrate to other locations in the body [15] providing these early cancer cells with the capacity to infiltrate the surrounding tissue and ultimately metastasize to distant sites [16].”
BackgroundOvercoming physical barriers in cancer therapy
Beyer, I., van Rensburg, R., & Lieber, A. (2013) · Tissue Barriers · doi:10.4161/tisb.23647 · Cited by 31
Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells
Trinh, S. X., Nguyen, H., Saimuang, K., Prachayasittikul, V., & Chan-on, W. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.2.473 · Cited by 30
“EMT is a crucial process that occurs during several stages of normal embryonic development, wound healing, and Asian Pacific Journal of Cancer Prevention, Vol 18 477 cancer progression (Turley et al., 2008).”
BackgroundLong Non-Coding RNAs in Epithelial-Mesenchymal Transition of Pancreatic Cancer
Takahashi, K., Taniue, K., Ono, Y., Fujiya, M., Mizukami, Y., & Okumura, T. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.717890 · Cited by 25
Xiang, M., Liang, L., Kuang, X., Xie, Z., Liu, J., Zhao, S., Su, J., Chen, X., & Liu, H. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16834 · Cited by 29
Epithelial–mesenchymal transition in pulmonary carcinosarcoma: case report and literature review
Thomas, V. T., Hinson, S., & Konduri, K. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011421949 · Cited by 25
“…resulting in decreased expression of epithelial cytokeratins, decreased expression of cell-to-cell adhesion proteins (E-cadherin and plakoglobin), and increased expression of vimentin, smooth-muscle actin, and fibronectin [Acloque et al. 2009; Voulgari and Pintzas, 2009; Turley et al. 2008].”
BackgroundRichter, M., Yumul, R., Wang, H., Saydaminova, K., Ho, M., May, D., Baldessari, A. E., Gough, M., Drescher, C. W., Urban, N. D., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.5 · Cited by 31
Excoffon, K. J. D. A., Bowers, J. R., & Sharma, P. (2014) · PubMed · Cited by 30
Arendt, L. M., Evans, L. C., Rugowski, D. E., Garcia-Barchino, M. J., Rui, H., & Schuler, L. A. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0221 · Cited by 24
“These kinases are implicated 367 in many processes in mammary tumorigenesis and progression, including proliferation, survival, the 368 epithelial to mesenchymal transition and altered relationship with the ECM, and invasion (Vivanco & 369 Sawyers 2002; Sebolt-Leopold & Herrera 2004; Turley et al. 2008), as well as tr…”
Wang, W., Zhao, Y. F., Yao, S., Cui, X., Pan, W., Huang, W., Gao, J., Dong, T., & Zhang, S. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917080089 · Cited by 24
CHEN, X.-M., GUO, J.-M., Chen, P., Mao, L.-G., FENG, W.-Y., LE, D.-H., & Li, K. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2523 · Cited by 23
Hashimoto, Y., Fukasawa, M., Kuniyasu, H., Yagi, K., & Kondoh, M. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13337 · Cited by 26
Zhou, L., Ouyang, T., Li, M., Hong, T., Alriashy, M. H. S., Meng, W., & Zhang, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.784672 · Cited by 28
Immunotherapy Targeting Colon Cancer Stem Cells
Iovino, F., Meraviglia, S., Spina, M., Orlando, V., Saladino, V., Dieli, F., Stassi, G., & Todaro, M. (2010) · Immunotherapy · doi:10.2217/imt.10.87 · Cited by 24
Zhang, Y., & Zhou, H. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4586 · Cited by 21
Sumsuzzman, D. M., Jin, Y., Choi, J., Yu, J., Lee, T. H., & Hong, Y. (2019) · Tumor Biology · doi:10.1177/1010428319892790 · Cited by 21
“EMT is a unique phenotypic switch by which epithelial cells deprive their polarity and receive the invasive features of mesenchymal cells in the process of metastasis.(44) Furthermore, studies have exhibited that IL-6 can incite EMT in a few cancerous cells, for example, pancreatic, lung, hepatic, and CRC.”
BackgroundJian-xin, L., Chen, Y., Cao, Z., Guan, B., Peng, J., Chen, Y., Zhan, Z., Sferra, T. J., Sankararaman, S., & Lin, J. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925598 · Cited by 20
“For example, E-cadherin and other epithelial markers are absent following EMT, whereas N-cadherin and vimentin, which are mesenchymal markers, are overexpressed.(7,8) In the EMT process, pleiotropic EMT-related transcription factors, such as zinc finger E-box binding homeobox (ZEB)1 and ZEB2 modulate the EMT phenotype.”
BackgroundInfluentialUmbreit, C., Flanjak, J., Weiß, C., Erben, P., Aderhold, C., Faber, A., Stern‐Straeter, J., Hoermann, K., & Schultz, J. D. (2014) · PubMed · Cited by 20
Hyaluronan and the Aggregating Proteoglycans
Wight, T. N., Toole, B. P., & Hascall, V. C. (2010) · Springer eBooks · doi:10.1007/978-3-642-16555-9_5 · Cited by 27
Balch, C., Naegeli, K. M., Nam, S., Ballard, B., Hyslop, A., Melki, C., Reilly, E. A., Hur, M., & Nephew, K. P. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20086 · Cited by 19
Ras Signaling in Breast Cancer
Moon, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_4 · Cited by 25
Cho, W. J., Oliveira, D. S. M., Najy, A. J., Mainetti, L. E., Aoun, H. D., Cher, M. L., Heath, E. I., Kim, H.-R. C., & Bonfil, R. D. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0829-5 · Cited by 19
“, lung) that promote mesenchymal-to-epithelial transition in colonizing cancer cells [71, 72].”
Liang, Y. (2022) · Glycoconjugate Journal · doi:10.1007/s10719-021-10032-w · Cited by 18
EBV promotes vascular mimicry of dormant cancer cells by potentiating stemness and EMT
Cheng, T., Zhang, S., Xia, T., Zhang, Y., Ji, Y., Pan, S. Y., Xie, H., Ren, Q., You, Y., & You, B. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113403 · Cited by 18
Ahn, Y., Lee, J.-C., Sung, M., & Heo, D. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803725 · Cited by 20
“In addition to inhibiting immune suppression, TGF- 1 is also involved in several mechanisms of tumor promotion, such as metastasis (9), angiogenesis, and the epithelial to mesenchymal transition (10).”
BackgroundChen, H., Shen, A., Zhang, Y., Chen, Y., Lin, J., Lin, W., Sferra, T. J., & Peng, J. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1549 · Cited by 19
“One of the mechanisms by which HIF-1 promotes cancer progression is through the induction of epithelial-mesenchymal transition (EMT), a process in which epithelial cells lose cell-cell adhesion and cell polarity, and acquire properties of mesenchymal cells (18-21).”
Verset, L., Tommelein, J., Lopez, X. M., Decaestecker, C., Mareel, M., Bracke, M., Salmon, I. J., Wever, O. D., & Demetter, P. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.290 · Cited by 17
Chia, S. L., Lei-Rossmann, J., Ferguson, D. J. P., Dyer, A., Fisher, K. D., & Seymour, L. W. (2017) · Virology · doi:10.1016/j.virol.2017.02.011 · Cited by 18
Fan, M., Qian, N., & Dai, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.7082 · Cited by 17
“EMT, the phenotypic conversion of epithelial cells to mesenchymal cells (46), is a highly conserved process that is essential in cancer initiation, invasion and metastasis (47).”
BackgroundCao, Z., Hao, Z., Xin, M., Yu, L., Wang, L., Zhang, Y., Zhang, X., & Guo, X. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0119-3 · Cited by 17
Sirtuins and Hypoxia in EMT Control
Aventaggiato, M., Barreca, F., Sansone, L., Pellegrini, L., Russo, M. A., Cordani, M., & Tafani, M. (2022) · Pharmaceuticals · doi:10.3390/ph15060737 · Cited by 20
“Type 3 EMT is a gradual process, with some cells retaining epithelial traits, others acquiring mesenchymal traits, and some becoming fully mesenchymal [43].”
BackgroundTong, J., Li, H., Hu, Y., Zhao, Z., & Li, M. (2022) · Journal of Cancer · doi:10.7150/jca.65822 · Cited by 16
“EMT also results in the lack of expression and function of epithelial markers, such as E-cadherin, and the upregulation of mesenchymal cell markers, such as N-cadherin and vimentin [13].”
BackgroundRegulation of miRNAs by Agents Targeting the Tumor Stem Cell Markers DCLK1, MSI1, LGR5, and BMI1
Sureban, S. M., Qu, D., & Houchen, C. W. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-014-0006-6 · Cited by 13
Pieniążek, M., Donizy, P., Ziętek, M., Szynglarewicz, B., & Matkowski, R. (2012) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1009653 · Cited by 17
“Chociaż EMT jest fizjologicznym procesem niezbędnym do prawidłowego rozwoju embrionalnego, jego aktywacja występuje także w niektórych stanach patologicznych, takich jak proces włóknienia czy progresja nowotworu złośliwego [6,93].”
BackgroundLi, S., Peng, D., Yin, Z., Zhu, W., Hu, X., & Liu, C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8459 · Cited by 14
“As demonstrated by western blot analysis, DEC1 overexpression significantly upregulated N‑cadherin and vimentin but downregulated E-cadherin in U2OS cells, whereas knockdown of DEC1 produced the opposite results in MG63 cells (Fig.”
BackgroundInfluentialKrawetz, R. J., & Kelly, G. M. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-014 · Cited by 13
Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements
Shao, S., Yang, X., Zhang, Y.-N., Wang, X., Li, K., Zhao, Y.-L., Mou, X., & Hu, P.-Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.835300 · Cited by 11
“In addition, during metastasis, phenotype alteration through epithelial-tomesenchymal transition (EMT) and then mesenchymal-toepithelial transition (MET) makes epithelial junctions tighten, which this event is not in favor of effective treatment (Christiansen and Rajasekaran, 2006; Turley et al., 2008).”
BackgroundSakakibara, J., Sakakibara, M., Shiina, N., Fujimori, T., Okubo, Y., Fujisaki, K., Nagashima, T., Sangai, T., Nakatani, Y., & Miyazaki, M. (2016) · Breast Cancer · doi:10.1007/s12282-016-0715-2 · Cited by 11
Role of Cancer Stem Cells in Spine Tumors: Review of Current Literature
Hsu, W., Mohyeldin, A., Shah, S. R., Gokaslan, Z. L., & Quiñones‐Hinojosa, A. (2012) · Neurosurgery · doi:10.1227/neu.0b013e3182532e71 · Cited by 12
Kiaheyrati, N., Babaei, A., Ranji, R., Bahadoran, E., Taheri, S., & Farokhpour, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122734 · Cited by 12
Epithelial-mesenchymal transition - A fundamental mechanism in cancer progression: An overview
Angadi, P. V., & Kale, A. D. (2015) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/2349-5006.174233 · Cited by 10
Yang, L., liu, J., Kong, X., Li, H., Shao, J., & Jiang, Z. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.06.002 · Cited by 9
El‐mezayen, H. A., El‐Kassas, M., El‐Taweel, F. M. A. A., Metwally, F. M., & Ghonaim, N. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.7.2541 · Cited by 9
“Characteristic combinations of CKs are expressed by different epithelia according to the organ of origin and differentiation (Turley et al., 2008).”
BackgroundZhang, K., Peng, T., Yan, Q., Sun, L., Miao, H., Li, Y., Hong, Y., Zhou, M., Guo, K., Zhang, L., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/1495768 · Cited by 9
“The main molecular features of EMT were as following: downregulation of E-cadherin and Occludin, upregulation of N-cadherin and Vimentin [17, 18] as well as ZEB1, Snail, Slug, and Twist that maintained EMT.”
BackgroundInfluentialChen, X., Qi, F., Shen, A., Chu, J., Sferra, T. J., Chen, Y., & Peng, J. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-2992-4 · Cited by 8
Gutiérrez-Castañeda, L. D., Tovar‐Parra, D., Quintero, G., Amezquita, L., Guerrero, C., & Sanabria, D. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29220 · Cited by 8
“Vang et al. (2013) used the medium DMEM with SFB and antibiotic, for cultivation of cell lines (SKOV3, IGROV 1, and 8 OVCAR).”
MethodSureban, S. M., May, R. J., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S. A., Pantazis, P., Rao, C. V., Postier, R. G., et al. (2019) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2019.1-32 · Cited by 8
A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment
Chen, C., Köberle, B., Kaufmann, A. M., & Albers, A. E. (2010) · Cancers · doi:10.3390/cancers2031528 · Cited by 7
“Although the EMT program is necessary for normal development, the aberrant activation of EMT contributes to various pathologic conditions, including fibrosis and carcinoma progression [45,46].”
BackgroundSaydaminova, K., Strauss, R., Xie, M., Bártek, J., Richter, M., van Rensburg, R., Drescher, C. W., Ehrhardt, A., Ding, S., & Lieber, A. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1219819 · Cited by 7
“a partial epithelial-tomesenchymal transition (EMT).(1) However, following invasion or metastasis, cells that have undergone EMT can also revert to”
BackgroundColeman, W. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00004-3 · Cited by 11
Das, S., Becker, B. N., Hoffmann, F. M., & Mertz, J. E. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s28 · Cited by 6
“Growth factors such as transforming growth factor-b (TGF-b) are required to induce and maintain EMT; they do so via both Smad-dependent and -independent signaling events [7-15].”
BackgroundInfluentialEl-Sharkawy, A., Atef, S., Abdel-Majeed, A., Eldaly, U., Elsherbiny, E. S., Metwally, F. M., & El‐mezayen, H. A. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.5.1725 · Cited by 5
“Characteristic combinations of CKs are expressed by different epithelia according to the organ of origin and differentiation (Turley et al., 2008).”
BackgroundSprouffske, K., & Maley, C. C. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_20 · Cited by 4
“However, tumors with a high proportion of cheaters are less able to compete against the host tissue and so there is selection to maintain low frequencies of migratory cheaters within the neoplasm, which is thought to be the case (Turley et al. 2008).”
BackgroundRaziky, M. E., Hafez, H. A., Elsharkawy, A. M., Moneer, T. A., Elsheikh, S., Maher, R., & Sharaf, S. A. E.-A. (2021) · Egyptian Liver Journal · doi:10.1186/s43066-021-00125-4 · Cited by 4
“Characteristic combinations of CKs are expressed by different epithelia according to the organ of origin and differentiation [13].”
Background
Metadata
- Authors
- Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J.
- Affiliations
- Western University (CA)
- Lawrence Berkeley National Laboratory (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Bissell, Mina J
- Venue
- Nature Clinical Practice Oncology
- Published
- 2008-03-18
- Volume
- 5
- Issue
- 5
- Pages
- 280-290
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- PMC
- PMC2846172
- OpenAlex
- W1972959587
- Cited by
- 253
- References
- 92
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 18 · 2016: 18 · 2015: 15 · 2014: 16 · 2013: 21 · 2012: 12
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA126552, R13CA113258, R37CA064786, R13CA098946, R01CA064786)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cellular plasticity, tumor progression, tumor invasion, metastasis, ERK1/ERK2 signaling, PI3K signaling, Ras signaling, tumor microenvironment, fibrosis
- MeSH terms
- Cell Transformation, Neoplastic, Epithelial Cells, Humans, Neoplasms, Neoplastic Processes, Disease Progression, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.